Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell Platform and Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell Platform and Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

Shots:

  • Adaptimmune to receive $50M up front, ~73.75M development milestones/ target (if product co-developed & co-commercialized by both companies) and $147.5M as milestones/product & $110M as commercial milestone if products developed by Astellas. Additionally, Adaptimmune to receive up to $7.5M/ yr. as research funding and royalties on net sales of the products
  • Astellas to receive and $147.5M as milestones/product & $110M as commercial milestone if products developed by Adaptimmune and royalties on net sales of the therapies. The companies will equally share the cost & profit of therapies co-develop & co-commercialize by the companies
  • The collaboration leverages Adaptimmune’s target identification and validation capabilities and Astellas’ universal donor cell and gene-editing platform. The agreement covers up to three T-cell therapies, following the completion of P-I study of each candidate, the companies will elect whether to co-develop & co-commercialize the candidate or allow the other company to develop in exchange of milestones & royalties

Click here ­to­ read full press release/ article | Ref: Adaptimmune | Image:  Adaptimmune